Oric Pharmaceuticals
Rakesh Vekariya is a Senior Scientist in Medicinal Chemistry at ORIC Pharmaceuticals Inc. since November 2021, having previously held the position of Scientist in Medicinal Chemistry at the same company. Prior experience includes a role as Drug Discovery Scientist I in Medicinal Chemistry at Vanderbilt University from May 2019 to October 2021, focusing on targeting Mcl-1 using fragment-based methods and structure-based design. Rakesh also worked as a Postdoctoral Researcher at Southern Research from August 2016 to April 2019, conducting structure-activity relationship studies on mu agonist/delta antagonist opioid analgesics, and participated in lead optimization. Earlier roles include Graduate Research Assistant positions at the University of North Carolina at Chapel Hill, The University of Kansas, and Virginia Commonwealth University. Rakesh earned a PhD in Medicinal Chemistry from The University of Kansas, a Master’s degree in Medicinal Chemistry from Virginia Commonwealth University, and a Bachelor of Pharmacy from J.S.S. College of Pharmacy, Ooty.
This person is not in the org chart
Oric Pharmaceuticals
ORIC Pharmaceuticals is a privately held, clinical-stage oncology company focused on making cancer treatments more effective by addressing mechanisms of resistance. ORIC's lead asset, ORIC-101, is a potent and selective small-molecule antagonist of the glucocorticoid receptor. ORIC's pipeline targets other undisclosed mechanisms of oncology therapy resistance. ORIC's scientific founders are Drs. Charles Sawyers, MD, and Scott Lowe, PhD, who have strong records of discovering innovative treatments and targets in cancer. The company has assembled strong leadership and scientific teams and a board with extensive experience in drug development and financing. ORIC is funded by leading biotechnology investors, including The Column Group, Topspin Partners, OrbiMed Advisors, EcoR1 Capital, Fidelity Management & Research Company, Trinitas Capital, Foresite Capital, Taiho Ventures, Memorial Sloan Kettering, Kravis Investment Partners, NS Investment and City Hill Ventures. ORIC is headquartered in South San Francisco, California.